Back to Search
BRETT BLASER, D.O.
D.O.
Family Medicine Physician
NPI: 1538471313Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
05-44396(KS)CL0039(NV)OC-0029(ID)50(WI)R1817(AZ)DO.1932(AL)66505(MN)9267007-1204(UT)
Research & Publications (20)
A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.
PMID 19660811·Leuk Res·2010
7-preclinical
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
PMID 19553639·Blood·2009
7-preclinical
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
PMID 17717597·J Clin Invest·2007
7-preclinical
Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia.
PMID 17554378·Leukemia·2007
7-preclinical
Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.
PMID 17110450·Blood·2007
7-preclinical
Parapharyngeal abscess by Aspergillus flavus in a neutropenic patient with myelogenous leukaemia.
PMID 17472625·Mycoses·2007
5-case
Audiological long-term results following stapedotomy with stapedial tendon preservation.
PMID 17245049·Adv Otorhinolaryngol·2007
8-other
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
PMID 17537993·Blood·2007
7-preclinical
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.
PMID 17875674·J Exp Med·2007
7-preclinical
Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
PMID 16516125·Best Pract Res Clin Haematol·2006
6-review
Fabry's disease: otoneurologic findings in twelve members of one family.
PMID 16805371·Ann Otol Rhinol Laryngol·2006
4-observational
Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.
PMID 16757683·Blood·2006
7-preclinical
Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
PMID 16740775·Clin Cancer Res·2006
7-preclinical
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.
PMID 16713975·Immunity·2006
7-preclinical
Tumor growth impedes natural-killer-cell maturation in the bone marrow.
PMID 16556890·Blood·2006
7-preclinical
STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo.
PMID 16482512·Eur J Immunol·2006
7-preclinical
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
PMID 16293596·Blood·2006
8-other
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.
PMID 15976176·Blood·2005
7-preclinical
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
PMID 16286244·Cancer Cell·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 475 40TH ST STE 111
OGDEN, UT 84403 - Phone
- (801) 515-7997
Quick Facts
- NPI
- 1538471313
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 8
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile